Fred Powell, Executive Vice President and Chief Financial Officer
Mr. Powell joined the Company in November of 2016 as Senior Vice President and Chief Financial Officer. Prior to joining Antares, from 2012 until 2016 Mr. Powell served as Vice President and Chief Financial Officer for Celator Pharmaceuticals, which was a publicly traded biopharmaceutical company engaged in the development of a portfolio of cancer therapies. At Celator, he was responsible for the Company’s accounting, corporate finance and financial planning functions. From 2011 until 2012, Mr. Powell was the chief financial officer of OraPharma, Inc. where he helped develop and grow the specialty healthcare company. Mr. Powell was chief financial officer of BMP Sunstone Corporation, a publicly traded U.S. specialty pharmaceutical company from 2005 until 2011. Mr. Powell also held senior finance and administration positions at Eximias Pharmaceutical Corporation, Innaphase Corporation and ERT. Mr. Powell began his career with KPMG Peat Marwick and holds a B.S. in Accounting from of Pennsylvania State University.
Peter J. Graham ESQ., Executive Vice President, General Counsel, Human Resources, Chief Compliance Officer and Corporate Secretary
Mr. Graham joined the Company in July 2015 as Senior Vice President, General Counsel, Chief Compliance Officer, Human Resources and Corporate Secretary and has more than 20 years of legal and executive management experience in publicly and privately held pharmaceutical and medical device companies. From 2010 until 2015, Mr. Graham served as Executive Vice President, General Counsel, Chief Compliance Officer and Global Human Resources for Delcath Systems, Inc. (NASDAQ: DCTH), a late-stage clinical development company focused on cancers of the liver. From 2008 until 2010, Mr. Graham was Vice President, General Counsel and a member of the Executive Committee of ACIST Medical Systems, Inc., a subsidiary of Bracco, SpA., a global company specializing in cardiovascular and diagnostic imaging solutions. Prior to ACIST, Mr. Graham spent 11 years at E-Z- EM, Inc. (NASDAQ: EZEM), a global medical device and pharmaceutical company specializing in CT and MR imaging solutions where he served as Senior Vice President, Chief Legal Officer, and Global Human Resources and Secretary. From 1997 until 2004, Mr. Graham also served as General Counsel and Corporate Secretary for AngioDynamics, Inc. (NASDAQ: ANGO), then a wholly owned subsidiary of EZEM, a leading provider of interventional medical devices. Mr. Graham earned his J.D. at Yeshiva University's Benjamin N. Cardozo School of Law in 1995, and his B.A. in Political Science at the University of Wisconsin-Madison.
James P. Tursi, M.D., Executive Vice President, Head of Research and Development and Chief Medical Officer
Dr. Tursi joined the company in August 2018 as Executive Vice President, Head of Research and Development and Chief Medical Officer. Prior to joining Antares, from 2015 until 2018, Dr. Tursi served as Chief Medical Officer for Aralez Pharmaceuticals, a public biopharmaceutical company focusing on cardiovascular disease and pain. From 2009 until 2015, Dr. Tursi started as Vice President of Research and Development with promotion to Chief Medical Officer for Auxilium Pharmaceuticals, a public biopharmaceutical company focusing on Urology, Men’s Health, Dermatology and Orthopedics. He led the highly successful Xiaflex® development program which resulted in multiple FDA approvals and product line extensions. Auxilium was acquired by Endo Pharmaceuticals for $2.6 billion completing in 2015. Prior to his tenure at Auxilium, Dr. Tursi worked in Clinical Development and Medical Affairs roles of increasing responsibility at GSK Biologicals on their cervical cancer vaccine and Procter & Gamble Pharmaceuticals on products for testosterone deficiency, inflammatory bowel disease and overactive bladder. Prior to entering the pharmaceutical industry, Dr. Tursi practiced Medicine and Surgery for over 10 years and created a medical education company, I Will Pass®, which assisted physicians in the process of board certification. Dr. Tursi received his Doctor of Medicine degree from the Medical College of Pennsylvania and completed his residency training at the Johns Hopkins Hospital. He currently sits on the Board of Directors of Agile Therapeutics, a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptives.
Edward Kessig, Senior Vice President, Commercial
Mr. Kessig joined Antares in December of 2016 as the Vice President of Sales and in March of 2018 he was promoted to Senior Vice President of Commercial Operations. He brings almost 25 years of Pharma experience to the company. The scope of his role includes the management and oversight of Antares’ current sales team selling Otrexup. In addition, Mr. Kessig will participate in the development of the commercial launch strategy for XYOSTED, our novel testosterone delivery device, and ultimately building out the sales team for the launch of XYOSTED. Prior to joining Antares Mr. Kessig held senior commercial roles at Lipocine as V.P. of Sales, ThromboGenics as US Commercial Head, Nuro Pharma as V.P. of Commercial Operations, Auxilium Pharmaceuticals as Senior V.P. of Sales, INOTherapeutics as North American Sales Director and various commercial roles at Elan Pharmaceuticals where he started as a sales representative in 1992.
Dr. Steven Knapp, Senior Vice President, Regulatory Affairs and Quality Assurance
Dr. Knapp is a seasoned regulatory and quality executive with over 30 years of experience in the pharmaceutical and device industry and a proven track record of building and managing regulatory and quality departments in both large and small organizations. Most recently, Dr. Knapp served as Vice President, Global Regulatory Affairs and Scientific Communications at Endo Pharmaceuticals. Prior to Endo, he was Global Vice President of Regulatory and Quality at Valeant Pharmaceuticals and served in a similar position at Ikaria. Earlier in his career, Steven spent 13 years at Bristol Myers Squibb (BMS) holding various positions of increasing responsibility in the regulatory affairs and quality assurance departments. Prior to BMS, Steve worked at Schering-Plough, in the area of International Regulatory Affairs, as well as J&J Research and Ortho Pharmaceuticals in the areas of pharmaceutical development and manufacturing. Dr. Knapp earned his Bachelor of Science in Pharmacy, Master of Science in Manufacturing/Packaging Engineering and Doctorate of Pharmacy from Rutgers University in New Brunswick, NJ.
Patrick Madsen, Senior Vice President, Operations
Mr. Madsen joined the Company in November 2010 as Vice President of Product Development, Parenteral Products Division. Prior to joining the Company, Mr. Madsen was employed at Hutchinson Technology Inc., from 1999 to 2010, in positions of increasing responsibility, most recently serving as Director of Engineering in the BioMedical Division. Mr. Madsen successfully led the development and commercial launch of Hutchinson’s advanced mobile sensors for monitoring tissue oxygenation. Prior to joining Hutchinson Technology, Mr. Madsen was employed by Boston Scientific Corporation, Inc. He holds a B.S. in Mechanical Engineering degree from the University of North Dakota.
Peter Sadowski, Ph.D., Senior Vice President, Technology Portfolio and Intellectual Property
Dr. Sadowski joined Medi-Ject Corporation, a predecessor company to Antares Pharma, in March 1994 as Vice President, Product Development. In 2001 Dr. Sadowski became Vice President of the Company’s Devices Group where he led the conceptualization and development of the VIBEX mini-needle injection technology platform. In 2009 he was promoted to Senior Vice President and General Manager, Parenteral Products Group. Prior to joining the Company, Dr. Sadowski led product development teams at Molecular Genetics, Inc., GalaGen, Inc., and American Biosystems, Inc. Dr. Sadowski holds a Ph.D. in microbiology from the University of Minnesota.
Henry R. Wolfe, PhD, Senior Vice President, Product Development
Dr. Wolfe joined Antares Pharma in January 2017 as Senior Vice President of Pharmaceutical Development with more than 30 years of experience in the pharmaceutical and biotechnology industry. Immediately prior to joining Antares, Dr. Wolfe was Vice President of Biologics at Sun Pharma where he was responsible for the development of an NCE monoclonal antibody (tildrakizumab) in both prefilled syringe and auto-injector forms. In an earlier role at Sun, Dr. Wolfe was Vice President of Generics R&D with roles in both pharmaceutical and clinical development. Prior to its acquisition by Sun, Dr. Wolfe was Vice President of Generics R&D at URL Pharma with responsibilities for pharmaceutical development, pharmacology/toxicology and 505b2 programs. Additionally, Dr. Wolfe was the Chief Scientific Officer at two biotechnology companies (CombiMab and Genaera) focused on the development of parenteral small molecules, peptide and protein NCEs. Dr. Wolfe received a BA degree in Biology from Towson University, an MS in Biochemistry and Nutrition from Virginia Polytechnic Institute and a PhD in Molecular Pharmacology and Structural Biology from